Peer-reviewed veterinary case report
Survival times for dogs with primary lung tumors after surgery
By Rose, Ruth J & Worley, Deanna R·Published in Frontiers in veterinary science·2020·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A Contemporary Retrospective Study of Survival in Dogs With Primary Lung Tumors: 40 Cases (2005-2017).
- Species:
- dog
Plain-English summary
A group of dogs with primary lung tumors underwent surgery to remove the affected lung lobe and had lymph nodes biopsied to check for cancer spread. The study found that dogs with cancer in their lymph nodes lived an average of 167 days after surgery, while those without lymph node involvement lived about 456 days. Interestingly, receiving chemotherapy after surgery did not seem to improve survival for either group. Overall, the findings suggest that while dogs with lung tumors can survive longer than previously thought, the presence of cancer in lymph nodes and larger tumor size can significantly reduce their survival time.
People also search for: dog lung tumor treatment · primary lung cancer in dogs · dog chemotherapy survival rates
Abstract
To report the median survival time in a contemporary cohort of dogs with primary lung tumors and intrathoracic nodal metastasis.Retrospective Case Series.Dogs with primary lung tumors treated with lung lobectomy and lymph node biopsy.The medical record database at Colorado State University was queried for dogs with primary lung tumors from January 1, 2005 to December 31, 2017. Patients were identified for inclusion if they had lung lobectomy and an intrathoracic lymph node biopsy performed. The median survival time (MST) for lymph node positive (LN+) and negative dogs (LN-) was calculated as well as the MST in dogs that did or did not receive adjuvant chemotherapy. Differences were compared between groups with significance set at< 0.05.The MST in LN+ dogs (= 11) was 167 days which was not statistically different from LN- dogs (= 29) at 456 days (= 0.2407). No significant difference in the MST in LN+ dogs was identified between dogs that received adjuvant chemotherapy (= 4; 110 days) and those that did not receive adjuvant chemotherapy (= 6; 125 days) (= 0.4409). There was no difference in survival time in LN- dogs receiving chemotherapy (= 12; 335 days) as compared to those LN- dogs (= 10) that did not receive adjuvant chemotherapy (258.5 days;= 0.6475).The survival of primary pulmonary neoplasia in dogs with intrathoracic nodal metastasis is longer than previously reported in this contemporary cohort. Chemotherapy did not appear to improve survival in LN+ or LN- dogs. The combination of tumor size between 100 and 999 cmand positive lymph node status significantly reduced survival.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33195509/